As nanowire size decreases, thermoelectric properties of nanowires can be enhanced. As a result, triangular nanowires with

side length of 1 nm have the best results of ZT and it can be enhanced to 1.5 and 0.85 for an n-type nanowire along [111] orientation and a p-type nanowire along [100] orientation, respectively. For extremely narrow nanowires, thermoelectric properties are only dependent on GSK126 cost the number of the transmission modes instead of material properties such as carrier effective mass. Moreover, cross-section shape and thermal conductance contributed by electrons play important roles in ZT while their influence can be ignored for large size nanowires. Even though smaller size nanowires have better performance with the consideration of the single nanowire thermoelectric properties, they might be less efficient than larger diameter nanowires, as packing space is not very dense. (C) 2010 American Institute of Physics. [doi:10.1063/1.3273485]“
“LY500307 is a selective estrogen receptor beta (ER) agonist that was developed for the treatment of benign prostatic hyperplasia. The in vitro functional selectivity of LY500307 for ER agonist activity is 32-fold above the activity at the alpha receptor (ER). LY500307

was evaluated in a series of male (M) and female (F) rat PKC412 ic50 fertility and rat and rabbit embryo-fetal development (EFD) studies, using 20 or 25 animals/group. LY500307 was administered daily by oral gavage starting 2 weeks (F) or 10 weeks (M) before mating, during cohabitation, until necropsy (M) or through gestation day (GD) 6 (F) in the fertility studies and from GD 6 to 17 (rats)

or GD 7 to 19 (rabbits) in the EFD studies. Dosage levels of LY500307 ranged from 0.03 to 10 mg/kg/day for rats and from 1 to 25 mg/kg/day for rabbits. Fertility, estrous, maternal reproductive endpoints, conceptus viability, sperm parameters, organ weights, and histopathology were evaluated in the fertility studies. Maternal reproductive endpoints and fetal viability, weight, and morphology were evaluated in the AR-13324 EFD studies. Toxicokinetics were assessed in satellite animals. At 10 mg/kg/day in the male fertility study, findings included decreased body weight (BW); food consumption (FC); fertility, mating, and conception indices; sperm concentration; and reproductive tissue weight (associated with atrophic histologic changes). In the female fertility study, effects included decreased BW and FC at 0.3 mg/kg/day and persistent diestrus, delayed mating, and reduced fertility/conception indices at 3 mg/kg/day. In the rat EFD study, findings included decreased maternal BW and FC and increased incidences of adverse clinical signs, abortion, maternal mortality/moribundity, postimplantation loss, and fetal skeletal variations at 3 mg/kg/day.